Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Pawel Kalinski, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses promising findings of a Phase I clinical trial (NCT03599453), which assessed a chemokine-modulating infusion in patients with triple-negative breast cancer. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.